About EyeYon
EyeYon is a company based in Ness Ziona (Israel) founded in 2011 by Nahum Ferera. EyeYon has raised $35.1 million across 3 funding rounds from investors including GF Securities, BPC Banking Tech and Quark Venture. EyeYon offers products and services including EndoArt® and Hyper-CL™. EyeYon operates in a competitive market with competitors including CorneaGen, Avedro, EyeGate, Cellusion and CorNeat Vision, among others.
- Headquarter Ness Ziona, Israel
- Founders Nahum Ferera
- SectorsHealthcare
- Website eye-yon.com
- Social LinkedIn X Facebook YouTube
- Total Equity Funding$35.1M (USD)
in 3 rounds
- Latest Funding Round$25M (USD), Series C
Mar 2021
- InvestorsGF Securities
& 7 more
Products & Services of EyeYon
EyeYon offers a comprehensive portfolio of products and services, including EndoArt® and Hyper-CL™.
Synthetic implant to treat corneal edema and replace donor tissues.
Contact lens that enhances bioavailability of topical eye drops for conditions.
Apps and channels of EyeYon
its YouTube channel EyeYon Medical has 32 subscribers and 5 videos.
Videos from EyeYon
The most watched videos on EyeYon's YouTube channel, EyeYon Medical (32 subscribers). Click a video to play it here.
More on EyeYon Medical.
Funding Insights of EyeYon
EyeYon has successfully raised a total of $35.1M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $25 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $35.1M
- Total Rounds 3
- Last Round Series C — $25M
- First Round $3.6M
(Apr 2015)
- Investors Count 8
All 3 funding rounds of EyeYon with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2021 | $25M | Series C | – | – | |
| Mar 2017 | $6.5M | Series A | – | Rimonci | |
| Apr 2015 | $3.6M | Series A | – | – |
8 investors in total: 8 institutional.
Investors in EyeYon
EyeYon has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include GF Securities, BPC Banking Tech and Quark Venture.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Tech & Life Sciences focused early stage VC firm investing in North America | – | quarkventure.com | Vancouver, Canada | |
Venture capital firm investing in early stage healthcare startups | – | triventures.vc | Herzliya, Israel | |
Limited information is provided about Rimonci's activities. | – | rimonci.com | - | |
Diamond Biofund is engaged in biotech investment and support. | – | diamondbiofund.com | Taipei, Taiwan | |
Pontifax Venture Capital is focused on life sciences investments. | – | pontifax.com | Herzeliya, Israel | |
Investments are directed toward Israeli technology startups by Docor. | – | docor.com | Tel Aviv, Israel | |
Provides payment processing, banking platforms, and commerce services worldwide. | 1995 | bpcbt.com | Baar, Switzerland | |
Provider of investment & asset management and financial services | 1991 | gf.com.cn | Guangzhou, China |
Investor details for EyeYon
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of EyeYon
11 people are tracked at EyeYon (8 in leadership, 3 in team).
| Name | Role | Group |
|---|---|---|
Nahum Ferera | Co-Founder & CEO | Leadership |
Anat Markovich Lemze | Director Medical Affairs & Product | Leadership |
Charles Holmes | Chief Commercial Officer (CCO) | Leadership |
Dmitry Dubson | Chief Technology Officer | Leadership |
Limor Leifenberg Kuznits | VP Clinical Affairs & Development | Leadership |
Hagit Rudich Wilf | Director QA | Leadership |
Ethan Nash | Chief Financial Officer | Leadership |
Efrat Gilboa | Director Of Medical Research | Leadership |
Oriah Mioduser | Senior Product Manager | Team |
Nicholas Helme | Lead Surgical Specialist EMEA | Team |
Fotis Tefos | Market Access Consultant - EU | Team |
Complete people profiles for EyeYon
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of EyeYon
3 dated milestones of EyeYon across 10 years, from founding to its latest funding, stage changes and deals.
- Founded EyeYon is founded.
- Funding First funding round of $3.6M.
- Funding Latest funding round, Series C, of $25.0M.
Competitors of EyeYon
EyeYon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CorneaGen, Avedro, EyeGate, Cellusion and CorNeat Vision, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| corneagen.com | 2017 | Seattle, United States | $42M | 205 | Therapeutic devices for corneal transplants are developed by CorneaGen. | |
| avedro.com | 2007 | Waltham, United States | $210.76M | 113 | Corneal collagen cross-linking technology is developed for ophthalmic applications. | |
| eyegatepharma.com | 1998 | Waltham, United States | $44.47M | 12 | Therapeutics and drug delivery systems for eye diseases are developed. | |
| cellusion.jp | 2015 | Minato, Japan | $29.71M | – | iPS cell-based technology for corneal endothelium regeneration is developed. | |
| corneat.com | 2015 | – | $4M | – | Nanotechnology-based artificial corneal implants are developed for ophthalmic use. | |
| nueyne.com | 2017 | Seoul, South Korea | – | – | Medical devices using electrical stimulation for health conditions are developed. | |
| recornea.com | 2019 | Udine, Italy | $161,997 | – | Provider of corneal implants devices for the treatment of eye diseases | |
| surgilum.com | 2010 | Wilmington, United States | – | – | Creates innovative technologies for ophthalmic surgical devices. |
Detailed competitors of EyeYon
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of EyeYon
The website of EyeYon (eye-yon.com) receives about 1K visits a month.
- Monthly visits1K
▲ 20.7% vs previous month
Websites whose visitors overlap most with EyeYon. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| facebook.com | 100% | 12.1B | #3 | View details | |
mail.google.com | mail.google.com | 100% | – | – | – |
Latest news on Eyeyon
Complete news archive for EyeYon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to EyeYon
10 companies that operate in the same segment as EyeYon (Ophthalmology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 | |
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. | 2003 | Alpharetta, Georgia, United States | USD 66.8 M | USD 80.75 M | 79 | |
AI-powered portable solutions for ophthalmic screening and diagnosis are developed. | 2009 | Bengaluru, Karnataka, India | USD 25.01 M | USD 4.85 M | 135 | |
Gene therapies for ocular and neurodegenerative diseases are developed. | 2015 | New York, New York, United States | – | USD 81.39 M | 381 | |
Small molecule therapeutics for ophthalmic disorders are developed. | 1987 | Watertown, United States | – | USD 31.37 M | 165 | |
Therapies for metabolic and orphan diseases are developed by Rezolute. | 2012 | Denver, Colorado, United States | – | – | 59 | |
Manufacturer of portable digital eye imaging devices and cloud-based healthcare platforms | 2010 | Bengaluru, Karnataka, India | USD 18.12 M | USD 4.78 M | 145 | |
Therapeutics for retinal diseases are developed by the company. | 2009 | Palo Alto, California, United States | USD 35.84 M | – | 109 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about EyeYon
EyeYon was founded in 2011 and raised its 1st funding round 4 years after it was founded.
EyeYon is headquartered in Ness Ziona, Israel. It is registered at Ness Ziona, Central District, Israel.
Nahum Ferera is the current CEO of EyeYon. They have also founded this company.
EyeYon is a funded company, having raised a total of $35.1M across 3 funding rounds to date. The company's 1st funding round was a Series A of $3.6M, raised on Apr 2015.
EyeYon was founded in 2011 in Ness Ziona, Israel, and operates in the ophthalmic medical device sector. Therapeutic contact lenses, such as the Hyper-CL, are developed for managing corneal pathologies. Additionally, the EndoArt implant, a polymer film attached to the posterior corneal surface, is created to address corneal edema resulting from endothelial dysfunction. Focus is placed on innovative solutions for eye-related conditions.
EyeYon offers EndoArt® and Hyper-CL™.
EyeYon has 8 investors. Key investors include GF Securities, BPC Banking Tech, Quark Venture, Triventures, and Rimonci.